We Are Excited to Announce Filtricine's Latest Round of Investment

August 3, 2021

We are excited to announce Filtricine's latest round of investment led by Boutique Venture Partners and Berkeley Catalyst Fund with the continuing participation of True Ventures, SOSV, Sand Hill Angels and Bluestein Ventures. Proceeds will be used to support our ongoing prostate cancer trial at Stanford University School of Medicine along with additional trials.Our prostate cancer clinical trial continues to recruit patients.


We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.
© 2022 Filtricine, Inc. All Rights Reserved | by Wuilt